ATE529511T1 - Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden - Google Patents
Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotidenInfo
- Publication number
- ATE529511T1 ATE529511T1 AT05851907T AT05851907T ATE529511T1 AT E529511 T1 ATE529511 T1 AT E529511T1 AT 05851907 T AT05851907 T AT 05851907T AT 05851907 T AT05851907 T AT 05851907T AT E529511 T1 ATE529511 T1 AT E529511T1
- Authority
- AT
- Austria
- Prior art keywords
- stimulative
- immuno
- oligonucleotides
- immunostimulatory
- oligonucleotide
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 6
- 230000028993 immune response Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003212 purines Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/042068 WO2007055704A2 (en) | 2005-11-07 | 2005-11-07 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE529511T1 true ATE529511T1 (de) | 2011-11-15 |
Family
ID=38023711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05851907T ATE529511T1 (de) | 2005-11-07 | 2005-11-07 | Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP2371956A3 (de) |
| JP (1) | JP5184366B2 (de) |
| CN (1) | CN101351228A (de) |
| AT (1) | ATE529511T1 (de) |
| AU (1) | AU2005338035B2 (de) |
| CA (1) | CA2628306C (de) |
| MX (1) | MX2008006005A (de) |
| WO (1) | WO2007055704A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| JP5737937B2 (ja) * | 2007-07-09 | 2015-06-17 | イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物 |
| JP5563455B2 (ja) * | 2007-08-01 | 2014-07-30 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の新規な合成アゴニスト |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CA3023451A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| TW244371B (de) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5912332A (en) | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| JP5268214B2 (ja) | 1999-08-13 | 2013-08-21 | イデラ ファーマシューティカルズ インコーポレイテッド | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調 |
| AU783687B2 (en) | 2000-01-26 | 2005-11-24 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| KR101123489B1 (ko) * | 2003-01-16 | 2012-03-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 개질된 면역자극성 디뉴클레오티드를 이용한 올리고뉴클레오티드-기재 화합물의 면역자극 특성의 조절 |
| US7427405B2 (en) * | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
-
2005
- 2005-11-07 AU AU2005338035A patent/AU2005338035B2/en not_active Ceased
- 2005-11-07 CN CNA2005800524843A patent/CN101351228A/zh active Pending
- 2005-11-07 JP JP2008538857A patent/JP5184366B2/ja not_active Expired - Fee Related
- 2005-11-07 WO PCT/US2005/042068 patent/WO2007055704A2/en not_active Ceased
- 2005-11-07 CA CA2628306A patent/CA2628306C/en not_active Expired - Fee Related
- 2005-11-07 AT AT05851907T patent/ATE529511T1/de not_active IP Right Cessation
- 2005-11-07 MX MX2008006005A patent/MX2008006005A/es active IP Right Grant
- 2005-11-07 EP EP11001257A patent/EP2371956A3/de not_active Withdrawn
- 2005-11-07 EP EP05851907A patent/EP1942945B1/de not_active Expired - Lifetime
- 2005-11-07 EP EP11003299.2A patent/EP2402442B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5184366B2 (ja) | 2013-04-17 |
| EP1942945A2 (de) | 2008-07-16 |
| EP2402442A3 (de) | 2012-03-28 |
| WO2007055704A2 (en) | 2007-05-18 |
| AU2005338035B2 (en) | 2012-06-07 |
| EP2371956A2 (de) | 2011-10-05 |
| JP2009514527A (ja) | 2009-04-09 |
| EP2402442B1 (de) | 2013-07-31 |
| CA2628306A1 (en) | 2007-05-18 |
| CN101351228A (zh) | 2009-01-21 |
| EP2371956A3 (de) | 2012-01-04 |
| CA2628306C (en) | 2014-06-17 |
| EP1942945B1 (de) | 2011-10-19 |
| AU2005338035A1 (en) | 2007-05-18 |
| EP2402442A2 (de) | 2012-01-04 |
| MX2008006005A (es) | 2008-10-01 |
| WO2007055704A3 (en) | 2007-12-06 |
| EP1942945A4 (de) | 2009-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20050100375A (en) | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | |
| WO2003057822A3 (en) | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | |
| CY1108870T1 (el) | Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους | |
| TW200738877A (en) | Immunostimulatory oligoribonucleotides | |
| DE50006758D1 (de) | Kovalent geschlossenes nukleinsäuremolekül zur immunstimulation | |
| NO20081884L (no) | Modulasjon av glukagonreseptorekspresjon | |
| NO20081883L (no) | Modulasjon av glukokortikoidreseptorekspresjon | |
| TNSN07150A1 (en) | Semi-soft c-class immunostimulatory oligonucleotides | |
| WO2006116458A3 (en) | Modified oligoribonucleotide analogs with enhances immunostimulatory activity | |
| NO20082448L (no) | Kombinasjoner av angiopoietin-2 antagonister og VEGF-A, KDR og/eller FLT1 antagonist for behandling av cancer | |
| WO2006089001A3 (en) | Lentiviral vectors and their use | |
| ATE536376T1 (de) | Humanes bindungsmolekül gegen cd1a | |
| MX2009008139A (es) | Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. | |
| TW200507874A (en) | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use | |
| WO2006104913A3 (en) | USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN | |
| ATE529511T1 (de) | Immunstimulatorische eigenschaften von verbindungen auf oligonukleotid-basis mit modifizierten immunstimulatorischen dinukleotiden | |
| MX2009012482A (es) | Oligonucleotidos de clase a con potencia inmunoestimuladora. | |
| CA3029451C (en) | Discontinuous oligonucleotide ligands | |
| WO2005014814A3 (en) | 5’-and 3’-capped aptamers and uses therefor | |
| ES2193958T3 (es) | Inmunoadsorbentes para el tratamiento de la septicemia. | |
| WO2009027978A8 (en) | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS | |
| EA200802307A1 (ru) | Бинарные смеси гиалуроновой кислоты и их терапевтическое применение | |
| EP1648910A4 (de) | Antisense-modulation der expression von stearoyl coa desaturase | |
| GB0300718D0 (en) | Proteins | |
| WO2004021978A3 (en) | Antisense modulation of endothelial specific molecule 1 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |